Perseus Proteomics Inc. [4882.T]
TOKYO, Jun 25 (Pulse News Wire) – Perseus Proteomics Inc. (4882.T) outlined its growth strategy through fiscal 2028, focusing on expanding its antibody drug pipeline and enhancing research support services.
The company plans to continue development activities for PPMX-T003 and PPMX-T002, despite not achieving desired outcomes yet. Clinical trials for PPMX-T003, aimed at aggressive NK cell leukemia, have been extended until March 31, 2027. In addition, Perseus Proteomics reported progress on PPMX-T004's pre-toxicity testing, aiming to optimize efficacy and toxicity balance. The company also secured funding of ¥100 million from AMED’s pharmaceutical support program for its clinical trial efforts.
Perseus Proteomics highlighted its commitment to advancing its antibody library technology and high-efficiency single B-cell platform, collaborating with Asuka Pharmaceutical Co., Ltd. and Eurus Therapeutics Co., Ltd. The firm expects continued growth in its antibody research support division, which has seen six consecutive quarters of revenue increases. Recognizing key risks such as competition and regulatory challenges, Perseus Proteomics emphasized ongoing efforts to mitigate potential setbacks through strategic partnerships and robust risk management strategies.
🟡 Confidence: Standard AI-translated content.